Document is current
Any future updates will be listed below
-
Authors
Parkin, James G. H.
Dean, Lareb S. N.
Bell, Joseph A.
Easton, Natasha H. C.
Edgeway, Liam J.
Cooper, Matthew J.
Ridley, Robert
Conforti, Franco
Wang, Siyuan
Yao, Liudi
Li, Juanjuan
Raj, Helen Vethakan
Downward, Julian
Gerlofs-Nijland, Miriam
Cassee, Flemming R.
Wang, Yihua
Cook, Richard B.
Jones, Mark G.
Davies, Donna E.
Loxham, Matthew
-
Funding
Funding for this research was provided by:
Wessex Medical Research
New Things Fund
Leverhulme Trust
Southampton Marine and Maritime Institute
Medical Research Council
Institute for Life Sciences, University of Southampton
Academy of Medical Sciences
Biotechnology and Biological Sciences Research Council
National Institute for Health Research Southampton Biomedical Research Centre
AAIR Charity
- License Information
-
More Information
Article History
Received: 19 September 2024
Accepted: 24 December 2024
First Online: 13 February 2025
Declarations
:
: Primary ATII cells were extracted from macroscopically normal human lung tissue deemed surplus to clinical diagnostic requirements, obtained following video assistant thoracoscopic surgery (VATS). Ethical approval was gained from the Southampton and South West Hampshire and the Mid and South Buckinghamshire Local Research Ethics Committees, and all subjects gave written informed consent.
: Not applicable.
: JD has acted as a consultant for AstraZeneca, Jubilant, Theras, Roche and Vividion and has funded research agreements with Bristol Myers Squibb, Revolution Medicines and AstraZeneca. DED. is co-founder of, shareholder in, and consultant to Synairgen Research Ltd. DED and MGJ acknowledge grants from Boehringer Ingelheim. ML is a member of the UK expert Committee on the Medical Effects of Air Pollutants (COMEAP). All other authors declare they have no competing interests.
